Anti-tumor agent comprising cytidine derivative and carboplatin
AssigneesTaiho Pharmaceutical Co., Ltd., Takuma Sasaki, Akira Matsuda
InventorHiromi Kazuno
Life of this patent
Estimating the term…
Abstract
Provision of a novel combined therapy with ECyd, which therapy exhibits remarkable antitumor effect and gives less adverse effects. The invention provides an antitumor agent containing, in combination, 1-(3-C-ethynyl-β-D-ribopentofuranosyl) cytosine or a salt thereof and carboplatin.
Claims12
An antitumor agent containing 1-(3-C-ethynyl-β-D-ribopentofuranosyl)cytosine or a salt thereof, and carboplatin in combination.
A method for treating cancer, comprising administering 1-(3-C-ethynyl-β-D-ribopentofuranosyl)cytosine or a salt thereof and carboplatin, to a patient in need thereof in combination.
A method for potentiating antitumor effect of carboplatin, comprising administering 1-(3-C-ethynyl-β-D-ribopentofuranosyl)cytosine or a salt thereof to a patient to which carboplatin is administered, in effective amount for the antitumor effect of carboplatin being significantly potentiated.
Dependencies are inferred from the claim text.